Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camptosar in metastatic breast cancer
NCT00004182Phase 2
Key facts
- Status
- Completed
- Start
- Oct 1999
- Primary completion
- Apr 2000
- Countries
- 1
- Sponsor
- Northwestern University
- Modality
- Small Molecules
- Drugs
- irinotecan
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in breast cancer, sponsored by Northwestern University. Primary endpoint: Objective Response Rate. Started Oct 1999; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Irinotecan Monotherapy
Patients receive irinotecan IV over 90 minutes weekly for 4 weeks. Treatment repeats every 6 weeks.
03
Who it enrols
Patients with histologically proven advanced breast cancer who have received prior anthracycline and taxane based chemotherapy, with measurable disease and no CNS metastases.
04
Endpoints
Primary
Objective Response Rate
Secondary
Toxicities
Survival Time
Duration of Response
Time to Treatment Failure
Beyond the preview
Go deeper on NCT00004182.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004182.